<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019056</url>
  </required_header>
  <id_info>
    <org_study_id>MG</org_study_id>
    <nct_id>NCT02019056</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the
      Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease
      and Alcoholic Hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in AST at 14weeks</measure>
    <time_frame>14Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the liver function to assess improvement of the MG on change in AST lab value assessed from baseline to  12 weeks in patients with Alcoholic fatty liver disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (Safety)</measure>
    <time_frame>14weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adverse Event: Physical examine, Lab test, Vital sign, ECG, symptom, start day and time, end day and time, severity, progress, outcome, relation with investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate ALT normalization</measure>
    <time_frame>14weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate ALT normalization assessed by comparing the percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate AST normalization</measure>
    <time_frame>14weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate AST normalization assessed by comparing the percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in AST, ALT, total lab billirubin lab value</measure>
    <time_frame>14weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of the MG on change in AST, ALT, total lab billirubin lab value assessed from baseline to 4, 8, 12 weeks in patients with Alcoholic fatty liver disease</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Alcoholic Fatty Liver Disease</condition>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>enteric coated capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metadoxine + garlic oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metadoxine + garlic oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metadoxine 500mg</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>enteric coated capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo /bid P.O</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MG-1</intervention_name>
    <arm_group_label>MG 500mg</arm_group_label>
    <other_name>MG500mg,Placebo /bid P.O</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MG-2 : MG1000mg, Placebo  /bid P.O</intervention_name>
    <arm_group_label>MG 1000mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metadoxine</intervention_name>
    <arm_group_label>Metadoxine 500mg</arm_group_label>
    <other_name>placebo, metadoxine 500mg/ bid P.O</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢Patients over 18, under 70 years of age

               -  The chronic alcohol intake patients

                    -  Current the heavy drinker over 3month, Day the average alcohol consumption
                       Male&gt;=60g, Female&gt;=40mg y-GTP increase Male&gt;=75, Female&gt;=35

               -  Over 1.5 ratio of AST to ALT

               -  Patients who have chronoc alcohol disease

        Exclusion Criteria:

          -  Patients who have liver disease with the cause different with the alcohol except

          -  Patients who have pyridoxine allergy or history

          -  Patients who are judged by investigator that participation of the study is difficult
             due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor,
             serious metabolic disease, severe renal disease, severe pulmonary disease, severe
             cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease
             and etc

          -  Patients taking other investigational product within 90 days prior to the
             participation in the study.

          -  Patients who has been taken any medications that could affect the treatment :
             hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic
             acid, pentoxifylline, lont-term use of NSAIDs, statins, neuroleptics, anti convulsive
             medications, high-dose acetaminophen(&gt;=2.5g/day)

          -  Patients who have received treatment that may affect liver function within 1 month
             prior to the participation in the study

          -  Patient who considered ineligible for participation in the study as Investigator's
             judgment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SooHyun Lee</last_name>
    <phone>82-31-739-3344</phone>
    <email>isuclala@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanyang university Hospital</name>
      <address>
        <city>Guri city</city>
        <state>Gyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misoon Park</last_name>
      <phone>82-31-554-3115</phone>
      <email>circle0@hmc.hanyang.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fatty Liver, Alcoholic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metadoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
